The strong Q2 beat and reaffirmed upper-end guidance confirm commercial momentum. The Regeneron partnership and convertible bond refinancing strengthen the balance sheet and pipeline optionality. Key catalysts to watch: Pixclara PDUFA date September 11, 2026, and Zircaix BLA resubmission timing.
Price Chart
Executive Summary
Telix Pharmaceuticals reported Q2 2026 revenue of US$247M, +21% YoY and +7% QoQ, driven by Precision Medicine (+30% YoY). FY2026 revenue guidance is tracking at the upper end of US$950M-$970M, with total 2026 revenue and other income expected to exceed US$1B including a US$40M non-refundable payment from Regeneron. The company also announced a strategic collaboration with Regeneron, a US$600M convertible bond refinancing extending maturities, and FDA alignment to advance the ProstACT Phase 3 trial of TLX591-Tx.
Key Facts
- Q2 2026 group revenue of US$247M, up 21% YoY and 7% QoQ
- Precision Medicine revenue of US$202M, up 30% YoY
- FY2026 revenue guidance tracking at upper end of US$950M-$970M, plus US$40M Regeneron payment
- R&D expenditure guidance updated to US$230M-$270M
- Entered strategic collaboration with Regeneron to develop next-gen radiopharmaceutical therapies
- Completed US$600M convertible bond refinancing, extending maturities to 2031
- FDA alignment on ProstACT Global Phase 3 trial of TLX591-Tx to advance to Part 2 in the US
- BiPASS Phase 3 study of Illuccix and Gozellix enrolled 338 patients
Financial Impact
Revenue growth of 21% YoY to US$247M in Q2, with FY2026 guidance implying >US$1B total revenue and other income
Risk Factors
- R&D expenditure guidance increased to US$230M-$270M, potentially pressuring near-term profitability
- Pipeline execution risk for late-stage trials (TLX591-Tx, TLX101-Tx, TLX250-Tx)
- Regulatory risk for Pixclara and Zircaix approvals
- Convertible bond issuance adds debt, though extends maturities
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001628280-26-048922 |
| Document: telix-6kforq22026tradingup.htm | 0001628280-26-048922 |
| Document: 0001628280-26-048922-index-headers.html | 0001628280-26-048922 |
| Document: 0001628280-26-048922-index.html | 0001628280-26-048922 |
| Document: 0001628280-26-048922.txt | 0001628280-26-048922 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 14, 2026 18d ago | 6-K | $12.83 $11.95 | ▼ −6.86% | ▼ −8.99% | $10.55 (−17.77%) |
Sep 14, 2026 18d ago | Press Release | $11.78 $11.31 | ▼ −3.99% | ▼ −4.10% | $10.55 (−10.44%) |
Sep 2, 2026 4w ago | 6-K | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Sep 1, 2026 4w ago | Press Release | $11.45 $11.90 | ▲ +3.93% | ▲ +4.89% | $10.55 (−7.86%) |
Aug 20, 2026 6w ago | 6-K | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Aug 20, 2026 6w ago | Press Release | $12.42 $11.38 | ▼ −8.41% | ▼ −9.53% | $10.55 (−15.06%) |
Jul 30, 2026 9w ago | Press Release | $9.89 $11.52 | ▲ +16.48% | ▲ +12.97% | $10.55 (+6.67%) |
Jul 21, 2026 10w ago | Press Release | $10.32 $10.10 | ▼ −2.13% | ▲ +0.27% | $10.55 (+2.23%) |
Jul 21, 2026 10w ago | 6-K | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
Jul 20, 2026 10w ago | Press Release | $10.92 $9.98 | ▼ −8.61% | ▼ −7.38% | $10.55 (−3.39%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access